The Schall Law Firm is investigating Qiagen N.V. for potential securities law violations after the company gave conflicting guidance on its QuantiFERON product's growth. In February 2026, Qiagen forecasted 6-7% growth for QuantiFERON, but by April, the CFO revised this, projecting sales to remain flat through 2026 and only normalize growth in 2027. This discrepancy has prompted a shareholder fraud investigation, and affected investors are encouraged to contact the law firm for potential legal action. The case highlights risks of misleading corporate forecasts impacting investor decisions.
Telsey Advisory lowered G-III Apparel Group's price target from $38 to $32, reflecting mixed financial results and challenges integrating the Marc Jacobs brand. The company's net sales dropped from $613.3 million to $554.1 million, but GAAP net incom...
The Toro Company reported strong third-quarter results, surpassing analyst expectations with earnings of $1.33 per share and revenues of $1.23 billion. This marks a year-over-year increase in earnings, reflecting improved profitability driven by stro...
Lands' End reported Q2 fiscal results with revenue rising 2.7% to $302 million, beating analyst expectations, while adjusted EPS missed slightly at $0.09 versus $0.10 forecast. The company improved profitability from a year ago, turning an adjusted l...
Planet Labs is set to report its Q2 earnings, with analysts expecting a loss of $0.02 per share, a 33.3% improvement from last year. Revenue is estimated at $104.12 million. Despite a significant stock decline, trading 27% below its 200-day average, ...
CVS Health reported a 7.3% revenue increase in Q2 to $106.1 billion and raised its full-year revenue forecast to at least $414 billion, alongside improved earnings per share guidance. Despite UBS lowering its price target to $118, analysts like Jeffe...
